Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.08%
#3 Tutorial Tutorial +6.71%
#4 Palladium Network Palladium Network +6.69%
#5 OpenEden OpenEden +6.37%
#6 EfficientFrontier EfficientFrontier +5.09%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +4.66%
#8 Momentum Momentum +4.55%
#9 Prom Prom +3.88%
#10 Bedrock Bedrock +3.76%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
BioSyntech, Inc. BioSyntech, Inc.

BioSyntech, Inc.

BSYI
Classificação em ações #40152
BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels... BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels aimed at both repairing tissues and delivering therapeutic compounds. The company's key product pipeline features BST-CarGel, a biodegradable gel designed for cartilage repair; BST-InPod, intended for alleviating heel discomfort; BST-DermOn, for managing and healing chronic wounds; BST-Ossifil, used in bone void filling; BST-Ossifix, which provides structural support for bones; and BST-Disc, focused on restoring intervertebral discs. Beyond these, BioSyntech offers injectable products leveraging BST-Gel technology to precisely deliver biotherapeutics. Its technological assets also include Arthro-BST, an arthroscopic device for the non-destructive evaluation of cartilage degradation or repair, and Mach-1, a micromechanical testing system for assessing the properties of various tissues and materials. The company also manufactures ultra-pure chitosans under the Ultrasan brand and offers both manufacturing and analytical services. Founded in 1994 and based in Laval, Canada, BioSyntech Inc. initiated administration proceedings under the Bankruptcy and Insolvency Act on May 12, 2010, and is currently undergoing reorganization.
Preço da ação
$0.00001
Última sincronização: 2025-09-24
Valor de mercado
$229.03K
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
CA
Negociar BioSyntech, Inc. (BSYI)

Categoria

Healthcare
Receita da BioSyntech, Inc. (BSYI)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da BioSyntech, Inc., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da BioSyntech, Inc. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE